Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02766270 : CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas
PhaseEarly Phase 1
AgesMin: 18 Years Max: 70 Years
Inclusion Criteria:

- Histologically confirmed supratentorial Diffuse low-grade and intermediate-grade
gliomas (World Health Organization grades II and III )

- IDH wild-type and TERT promoter mutation

- Age > 18

- Karnofsky performance score > 60

- Neutrophilic granulocyte count > 1500/µl

- Platelet count > 100 000/µl

- Hemoglobin > 10 g/dl

- Serum creatinine < 1.5 times the lab's upper normal limit

- AST or ALT < 1.5 times the lab's upper normal limit

- Adequate medical health to participate in this study

- No previous systemic chemotherapy

- No previous radiotherapy to the brain

- Written informed consent

Exclusion Criteria:

- Serious medical or neurological condition with a poor prognosis

- Contraindications to radiotherapy or temozolomide chemotherapy

- Patient unable to follow procedures, visits, examinations described in the study

- Second cancer requiring radiotherapy or chemotherapy

- Inability to undergo gadolinium-contrasted MRIs

- Pregnant women or nursing mothers can not participate in the study
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557